Zobrazeno 1 - 3
of 3
pro vyhledávání: '"J W, Kylstra"'
Autor:
Jonathan A. Bernstein, L. A. Hanby, Robert A. Nathan, T. Montanaro, Anjuli Nayak, Joseph H. Butterfield, R. G. Townley, J. A. Colton, S. Chodosh, Michael Schatz, Z. M. Munk, A. C. DeGraff, P. V. Williams, J. R. Taylor, T. B. Edwards, D. L. Southern, Paul H. Ratner, C. A. Bruce, T. D. Bell, M. Cohen, A. Floreani, William J. Calhoun, J. P. Kemp, S. Pollard, S. C. Campbell, L. Kirby, S. Weiss, T. W. Littlejohn, D. Auerbach, S. A. Gillman, S. P. Galant, J. W. Kylstra, S. R. Hirsch, William E. Berger, C. M. Bonuccelli, H. J. Schwartz, R. V. Albery, Frank C. Hampel, L. A. Weiss, Sheldon L. Spector, D. M. Lang, L. J. Rossoff, M. S. Rowe, T. J. Chu, P. J. Hannaway, D. Q. Mitchell, D. W. Aaronson, R. J. Dockhorn, J. P. O'Connor, Stanley Goldstein, Leonard Bielory
Publikováno v:
Journal of Allergy and Clinical Immunology. 102:935-942
Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma.We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5b57e701fd1db3f1b6ca6cb78b87b3
https://doi.org/10.1016/s0091-6749(98)70331-8
https://doi.org/10.1016/s0091-6749(98)70331-8
Autor:
W W, Hong, I W, Rak, V T, Ciuryla, A M, Wilson, J W, Kylstra, H Y, Meltzer, W T, Carpenter, A, Lehman, L A, Arvanitis
Publikováno v:
Schizophrenia research. 32(1)
Treating schizophrenia is expensive. Preventing rehospitalization of patients with schizophrenia provides an attractive opportunity for cost savings, especially for patients with 'revolving-door' or multiple-episode schizophrenia. Reducing the occurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1befc325a7d467dcde695c06c19749a
https://pubmed.ncbi.nlm.nih.gov/9690334
https://pubmed.ncbi.nlm.nih.gov/9690334
Publikováno v:
Journal of Clinical Oncology. 29:8048-8048
8048 Background: At the time of regulatory approval of 90-Y ibritumomab tiuxetan (Zevalin Z), 3 countries (USA, Switzerland, Japan) required labeling specifying that a 111-In imaging scan be perfor...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a2fdd99bbe7cc9b4ad2663eca2296a3
https://doi.org/10.1200/jco.2011.29.15_suppl.8048
https://doi.org/10.1200/jco.2011.29.15_suppl.8048